2353-33-5

Product Details:

CasNo： 2353-33-5

Molecular Formula： C8H12N4O4

Purity： 99%

Synonyms: 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 5-Aza-2'-deoxycytidine; 4-Amino-1-(2-deoxy-β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Decitabine(NSC127716); 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-on; 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-one; 5-azadeoxycytidine; 5-triazin-2(1h)-one,4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-3
alpha: D22 +68.5° (30 min) +57.8° (6 hr) (c = 0.5 in water)
Boiling point: 370.01°C
Density: 1.3771
Refractive index: 1.6590
Solubility: acetic acid/water (1:1): 50 mg/mL
Pka: 14.02±0.60
Color: White to Off-white
Form: Powder
storage temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

Uses:
Decitabine, also known as 5-Aza-2'-deoxycytidine or 2'-deoxy-5-azacytidine, is a cell cycle S phase-specific drug used to treat myelodysplastic syndromes (MDS.)
 

Mechanisms of Action：
Demethylating agents can regulate gene expression by activating tumor suppressor genes and enhancing the differentiation of genes, which help treat MDS. Decitabine is a natural andenosine analogue of 2′-deoxycytidine, known to the be strongest methylation specific inhibitor of DNA. After phosphorylation it can inhibit DNA methyltransferase, reducing DNA methylation, leading to demethylation of tumor cells, which can restore the normal functioning of genes, thus inhibiting tumor cell proliferation and preventing the occurrence of drug resistance. Decitabine inhibits DNA methylation in vitro, but does not affect its synthesis. Moreover, non-proliferating cells are not sensitive to it. Decitabine has anti-tumor activity and is characterized by a dual mechanism based on dose differences. At high concentrations it is cytoxic, while at low concentrations it is demethlyating.

Synthesis：

Air & Water Reactions：

Probably light and air sensitive. Water soluble. Decomposes in aqueous solution at a rate that depends on pH: at pH 7 the drug is more stable than at pH 9, but is less stable than at pH 6. At pH 7 and 99°F, approximately 7% conversion occurs in 1 hour.

Description：
Decitabine, 5-aza-2'-deoxycytidine, has been launched for the treatment of myelodysplastic syndromes (MDS). MDS are a set of hematologic disorders affecting the bone marrow that result in ineffective formation and development of blood cells. Furthermore, patients with MDS have a high risk of progressing to acute myeloid leukemia (AML). Traditional treatments include blood transfusions, hematopoietic growth factors, and prophylactic antibiotics, but these measures merely improve the quality of life with questionable effects on disease modification. While stem-cell transplantation is an aggressive, potentially curative approach, the advanced age or the other complicating health issues of most patients preclude them from considering this option. Recent advances in the underlying etiology of MDS, however, have led to the development of a new class of compounds known as demethylating agents. Decitabine follows the successful introduction of the first DNA methyltransferase inhibitor azacitidine.